Resources
Principal content
J&J stays true to its diversified model
Johnson & Johnson defends its strategy, with its three broad divisions of medical devices, consumer health and pharmaceuticals, even as the approach fails to shield it from industry pains
Philip Morris ordered to pay $300m to smoker
A Florida jury orders cigarette maker Philip Morris USA to pay $300m in damages to a 61-year-old ex-smoker who is wheelchair-bound by emphysema
Under-fives get swine flu jabs
Children under five will be the next group to be given priority in receiving the swine flu vaccine, Sir Liam Donaldson, the chief medical officer, said yesterday. The...
Cheap does not mean cheerful, says Toys R Us
This year's hard-to-find Christmas toy in the US, the Zhu Zhu Pets robotic hamster, costs about $10. But as he flips through Toys R Us's annual catalogue at the...
Regulations trim growth at United Drug
Reduced prices in its main Irish markets have crimped sales growth at the healthcare products supplier, in spite of strong growth in its contract sales and drug packaging businesses
Property concerns prompt NHS probe
An inquiry is being opened into how far the health service should retain control of its property when it puts services out to tender or allows mergers and takeovers
GSK deal draws smokers’ vaccine closer
The NicVAX vaccine moved closer to the market after a deal between GlaxoSmithKline and the US biotech company Nabi Pharmaceuticals, which developed the product
GSK plans to cut drug production waste
The UK-based pharmaceutical group has set a target to cut by two-thirds the waste generated by medicines production
Grandma knows best when it comes to drugs
A small cluster of British drug companies is marketing drugs that are decades old, relying on consumers’ affection for products that they probably first saw in their grandparents’ medicine chest
Asian growth boosts sales at Synergy
Strong demand for the decontamination of hospital equipment in Asia and Europe has buoyed revenues at Synergy Healthcare, the health services company.
Related content and features
Track this Topic
Recent drugs and healthcare reports
Market research reports
| Report name | Author | Publish date | Cost |
|---|---|---|---|
| Freedonia Focus on Cancer Therapies | Freedonia Focus | 11/30/2009 | $500 |
| United States Type 2 Diabetes Market | Intellent | 11/14/2009 | $7500 |
| Snapshots South Africa Pharmaceuticals 2009 | Snapdata International Group | 11/12/2009 | $600 |
| Snapshots US OTC Pharmaceuticals 2009 | Snapdata International Group | 11/12/2009 | $600 |
| Snapshots Hungary Pharmaceuticals 2009 | Snapdata International Group | 11/12/2009 | $600 |








